More About The Prasad Adusumilli Lab Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Adam Bograd

Research Fellow

Start Year

2010

End Year

2012

Awards and Scholarships

NIH T-32 Research Fellowship

Current Employment

Clinical Fellow (Thoracic Track), Memorial Sloan Kettering Cancer Center, New York, NY

Publications

Manuscripts

Abstracts/Presentations

  • Morello A, Zeltsman M, Bograd A, Jones DR, Adusumilli PS. Mechanistic insights into CAR T-cell efficacy in the treatment of heterogenous antigen expressing lung adenocarcinoma. International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer. December 4-7, 2016; Vienna, Austria.
  • Morello A, Villena-Vargas J, Mayor M, Bograd AJ, Jones DR, Sadelain M,  Adusumilli PS. Mesothelin-Targeted CAR T-Cell Therapy for the Treatment of Heterogeneous Antigen-Expressing Lung Adenocarcinoma. International Association for the Study of Lung Cancer (IASLC) 16th World Conference on Lung Cancer. September 6-9, 2015; Denver, CO.
  • Bograd AJ, Villena-Vargas J, Colovos C, Kachala S, Jones DR, Sadelain M, Adusumilli PS. Beneficial Role of Antigen Commensalism in Mesothelin-Targeted T-cell Therapy for Lung Adenocarcinoma. 18th Annual C. Walton Lillehei Resident Forum. April 27, 2015; New York, NY.
  • Bograd A, Villena-Vargas J, Kachala S, Servais E, Colovos C, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin-targeted T-cell therapy optimized for the lung adenocarcinoma tumor microenvironment. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer. October 27-30, 2013; Sydney, Australia.
  • Bograd A, Kadota K, Lee MC, Sarkaria IS, Rusch VW, Travis WD, Adusumilli PS. Tumoral neutral endopeptidase (CD10) expression predicts risk of recurrence, and further stratify intermediate-grade histology patients in stage I lung adenocarcinoma. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer. October 27-30, 2013; Sydney, Australia.
  • Kachala S, Bograd AJ, Rodriguez L, Servais EL, Kadota K, Sima C, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin decreases recurrence-free survival in lung adenocarcinoma by imparting an aggressive phenotype. American Association for Thoracic Surgery Meeting. May 4-8, 2013; Minneapolis, MN.
  • Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Sadelain M, Rusch VW, Adusumilli PS. Mesothelin promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in malignant pleural mesothelioma (MPM) patients: a potential mechanism for MPM regional aggressiveness. American Association for Thoracic Surgery 2012, Lillehei Forum. May 2012; San Francisco, CA.
  • Servais EL, Nitadori J, Morales EA, Suzuki K, Bograd AJ, Rizk NP, Downey RJ, Rusch VW, Adusumilli PS. Pre-operative consolidation to tumor ratio on computed tomography and FDG-PET SUVmax predict recurrence after limited resection of early lung adenocarcinoma. American Association for Thoracic Surgery 2012. May 2012; San Francisco, CA.